



First Quarter 2022

Earnings Highlights

\$25.7B

Revenue
+82% Op Growth¹

\$1.37

Rep. Dil. EPS
+59% Growth¹

\$1.62

Adj. Dil. EPS²
+76% Op Growth¹

\$2.3B

Rep. R&D Expenses
+16% Op Growth¹

\$2.3B

Adj. R&D Expenses³
+16% Op Growth¹

FY 2022 Guidance³
Revenue
\$98B–\$102B
Adj. Dil. EPS² \$6.25–\$6.45

\$4.2B

Returned to Shareholders
\$2.0B Share Repurchases
\$2.2B Cash Dividends

"I am very proud of our performance this quarter, both from a financial perspective and from the standpoint of trying to be a force for good in the world. We will continue to do all we can to support the health of all people, which is in line with our purpose: Breakthroughs that change patients' lives."

Albert Bourla
Chairman and Chief Executive Officer



Key Growth Drivers⁴

Pfizer-BioNTech
COVID-19 vaccine

\$13,227M Revenue

Eliquis
(apixaban) tablets

\$1,793M Revenue
+12% Op Growth

Pvovnar Family

Pneumococcal
Conjugate Vaccine

\$1,565M Revenue
+23% Op Growth

New Therapy
PAXLOVID™

COVID-19 Oral Treatment

\$1,470M Revenue

IBRANCE
palbociclib

\$1,237M Revenue
+1% Op Growth

Vyndamax
(talimide)

\$612M Revenue⁵
+41% Op Growth

Oncology Biosimilars

\$464M Revenue
+35% Op Growth

Pipeline Spotlights

Pfizer-BioNTech
COVID-19 vaccine

Expanded emergency use of second booster doses in ages 50+ and immunocompromised patients ages 12+

Proposed Acquisition
REVIRAL™

Entered agreement to acquire clinical-stage biopharma and its novel antiviral candidates for respiratory syncytial virus (RSV)

Candidate
RSVpreF
Vaccine

Received FDA Breakthrough Therapy Designations for RSV prevention in adults 60+ and for maternal protection

Completes Acquisition
ARENA
PHARMACEUTICALS

Completed acquisition of late-stage biotechnology company focused on immuno-inflammatory therapies

Candidate
Etrasimod

Positive Phase 3 top-line results in treating moderately to severely active ulcerative colitis

Approved in EU
APEXXNAR™
Pneumococcal Conjugate Vaccine

Approved for prevention of invasive pneumococcal disease and pneumonia in individuals 18+

Candidate
Fordadistrogene Movaparvovec

Re-start of Phase 3 CIFFREO study, including in U.S. for Duchenne muscular dystrophy gene therapy

Candidate
Lyme Disease VLA15 vaccine

Positive results from Phase 2 pediatric study, to progress to Phase 3 trial

Vaccines Internal Medicine Inflammation/Immunology Oncology Rare Disease Hospital



~468M

patients reached worldwide with our medicines and vaccines,⁶ a 140% increase from prior-year quarter

Nearly

3.4B

COVID-19 vaccine doses shipped to 179 countries to date

Advancing Robust Portfolio

Anticipated in the Next 18 Months⁷

Up to

16

Potential Approvals



Up to

19

Projected Pivotal Readouts



Up to

15

Potential Proof of Concept Readouts



What's Next

Reaffirm projected revenue CAGR of at least 6% and double-digit adjusted diluted EPS² growth through 2025⁸



Maintain

patient-centricity



Scale

emerging tech platforms



Invest

in areas we can win



Foster

a culture of innovation




Reduce

approval development cycle time

25 BY 2025

Ambition of up to 25 breakthrough launches in patients' hands by 2025



investors.pfizer.com

Please reference Pfizer's Q1 2022 earnings release and SEC filings for additional information.

¹ Operational revenue growth. Referenced to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.

² Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and reported EPS attributable to Pfizer Inc. common shareholders—diluted before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. Adjusted research and development (R&D) expenses is an income statement line item prepared on the same basis as, and therefore a component of, the overall Adjusted income measure. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the first quarter of 2022 and 2021 accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated May 3, 2022. The Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2021 Annual Report on Form 10-K and the Non-GAAP Financial Measure: Adjusted Income section accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated May 3, 2022 for additional information.

³ Total company guidance.

⁴ Q1 financial performance.

⁵ Presented figures include sales of both Vyndaqel and Vyndamax.

⁶ Patient counts are estimates derived from multiple data sources.

⁷ Reference the full set of materials in the Q1 2022 Earnings Presentation for certain information regarding potential approvals and projected pivotal and proof of concept readouts.

⁸ Projected revenue CAGR calculated from 2020–2025. Excludes the impact of Pfizer-BioNTech COVID-19 vaccine (Comirnaty) and the COVID-19 oral treatment (Paxlovid), recent or subsequent business development activities or potential future mRNA programs.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, product pipeline, in-line products and product candidates, business plans and prospects, manufacturing and product supply and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2021, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.

© 2022 Pfizer Inc. All rights reserved.